Alaunos Therapeutics
TCRT | NASDAQ
$1.62
-$0.01 (-0.61%)
At close: Nov 16, 2026, 3:59 PM ET
$1.56
-$0.06 (-3.70%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-0.61%
(1D)No price chart data available for 1D timeframe.
Rating
18.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #1000/1021 (Top 98%)
Key Statistics
Market Data
Market Cap $5.57M
1D Range
1.58 1.68
52W Range
0.74 4.36
Valuation (TTM)
PE -0.83
PB 8.55
EV/EBITDA -1.37
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $0.00
Cash Flow
FCF Yield -50.7%
SBC Adj. FCF Yield -55.6%
SBC Impact -9.7%
Margins
Gross Margin -28133.3%
Operating Margin -135266.7%
FCF Margin -94166.6%
Growth (CAGR)
Revenue 3Y | 5Y -89.9% |
-55.6%
Dil EPS 3Y | 5Y 91.7% |
59.8%
FCF 3Y | 5Y 94.7% |
55.3%
Returns
ROA -264.5%
ROE -232.6%
ROIC -622.4%
Financial Health
Net Cash
$124K
Current Ratio 0.77
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Librar...
Sector Healthcare
Industry Biotechnology
Employees 1
IPO Date Aug 24, 2005
Website www.alaunos.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove TCRT